Articles By Cyndi Root

  1. Alnylam, Medicine's Company Start Phase 1 Trial Of ALN-PCSsc In Hypercholesterolemia 12/15/2014

    Alnylam Pharmaceuticals and The Medicines Company announced that they have begun a Phase 1 trial of ALN-PCSsc for the treatment of hypercholesterolemia.

  2. NIH Awards Grant For Melior's Diabetes Candidate, MLR-1023 12/15/2014

    Melior Discovery announced in a press release that it has been awarded a grant from the National Institutes of Health (NIH) to continue its studies on MLR-1023, a novel insulin sensitizer.

  3. Ariad Announces Safety And Efficacy Data For Ponatinib In Leukemia Trials 12/12/2014

    Ariad Pharmaceuticals has announced safety and efficacy data from Phase 1 and 2 trials of Iclusig (ponatinib). The company announced the findings in press releases, stating that it is presenting the data at the annual meeting of the American Society of Hematology (ASH) in San Francisco, CA.

  4. Takeda's Ixazomib Effective As Multiple Myeloma Maintenance Therapy, Study Finds 12/11/2014

    Takeda Pharmaceutical Company announced that a Phase 2 study of single-agent ixazomib (MLN9708) demonstrated feasibility for the agent as a maintenance therapy for patients with multiple myeloma (MM).

  5. Novo Nordisk Reports Phase 3 Data On NovoEight In Hemophilia 12/10/2014

    Novo Nordisk’s Phase 3 trial of NovoEight (turoctocog alfa) has shown bleeding reductions in people with hemophilia A.

  6. FDA Approves Amgen's Xgeva For HCM 12/10/2014

    The Food and Drug Administration (FDA) has approved Amgen’s Xgeva (denosumab) to treat hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

  7. NIH Says Single IRBs Reduce Delays In Multi-Center Studies 12/9/2014

    National Institutes of Health (NIH) announced in a press release, that it is promoting single IRBs for multi-site studies instead of multiple Institutional Review Boards (IRBs).

  8. CRO Noble Acquires CRO Spring Valley Laboratories, Expands Preclinical Capabilities 12/9/2014

    Noble Life Sciences, a contract research organization (CRO) from Gaithersburg, MD, has acquired Spring Valley Laboratories from Sykesville, MD.

  9. FDA Approves Amgen's Blincyto For Rare Blood And Bone Marrow Cancer 12/8/2014

    Amgen has a new immunotherapy, approved under an accelerated review by the Food and Drug Administration (FDA).

  10. Biogen Idec Moves Aggressively, Advances Alzheimer Drug InTo Phase 3 12/8/2014

    Biogen Idec captured the spotlight recently, announcing that it was skipping Phase 2 and moving its experimental drug for Alzheimer’s disease (AD) into Phase 3 clinical trials.